Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon α-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany-Reference-Cited by-同舟云学术

Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon α-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany

Published:2005-06 Issue:2 Volume:6 Page:112-123
ISSN:1618-7598
Container-title:The European Journal of Health Economics
language:en
Short-container-title:Eur J Health Econ

Author:

Siebert Uwe,Sroczynski Gaby,Wasem Jürgen,Greiner Wolfgang,Ravens-Sieberer Ulrike,Aidelsburger Pamela,Kurth Bärbel M.,Bullinger Monika,Graf von der Schulenburg J.-Matthias,Wong John B.,Rossol Siegbert

Publisher

Springer Science and Business Media LLC

Subject

Health Policy,Economics, Econometrics and Finance (miscellaneous)

Link

http://link.springer.com/content/pdf/10.1007/s10198-005-0280-7.pdf

Reference99 articles.

1. Alter HJ, Seef LB (2000) Recovery, persistence, and sequelae in hepatitis c virus infection: a perspective on long-term outcome. Semin Liver Dis 20:17–35

2. Alter MJ, Kruskon-Moran D, Nainan OV, McQuillan GN, Gao F, Moyer LA, Kaslow RA, Margolis HS (1999) The prevalence of hepatitis C virus infection in the United States 1988 through 1994. N Engl J Med 341:556–562

3. Anonymous (1994) Sclerotherapy for male alcoholic cirrhotic patients who have bled from esophageal varices: results of a randomized, multicenter clinical trial. The Veterans Affairs Cooperative Variceal Sclerotherapy Group. Hepatology 20:618–625

4. Anonymous (1996) St. Anthony’s DRG guidebook 1995. St. Anthony: Alexandria

5. Anonymous (1999) EASL International Consensus Conference on hepatitis C. Paris, 26–27 February 1999. Consensus statement. J Hepatol 31:3–8

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quality of life in patients with chronic hepatitis C infection: Severe comorbidities and disease perception matter more than liver-disease stage;PLOS ONE;2019-05-03

2. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France;Journal of Viral Hepatitis;2018-05-09

3. Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany;PLOS ONE;2017-01-03

4. Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case;Journal of Viral Hepatitis;2016-05-04

5. Cost–effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C;Expert Review of Pharmacoeconomics & Outcomes Research;2015-08-29